P53, stem cells, and reprogramming: Tumor suppression beyond guarding the genome

Genes and Cancer

Volumn 2, Issue 4, 2011, Pages 404-419

  Spike, Benjamin T ^a   Wahl, Geoffrey M ^a  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

cancer; dedifferentiation; p53; plasticity; reprogramming; stem cell

Indexed keywords

ARF PROTEIN; BMI1 PROTEIN; DACTINOMYCIN; MUTANT PROTEIN; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53; REACTIVE OXYGEN METABOLITE;

APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER PREVENTION; CANCER STEM CELL; CANCER THERAPY; CARCINOGENESIS; CELL ACTIVITY; CELL CYCLE ARREST; CELL DAMAGE; CELL DEDIFFERENTIATION; CELL DIFFERENTIATION; CELL FUNCTION; CELL GROWTH; CELL HETEROGENEITY; CELL KINETICS; CELL MATURATION; CELL METABOLISM; CELL PROLIFERATION; CELL RENEWAL; CELL SURVIVAL; CELL TRANSPLANTATION; CELLULAR STRESS RESPONSE; DESMOSOME; DISEASE ASSOCIATION; DNA DAMAGE; EMBRYO DEVELOPMENT; EMBRYONIC STEM CELL; GENE ACTIVATION; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSFORMATION; GENOME ANALYSIS; GENOTOXICITY; HEMATOPOIETIC STEM CELL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR DYNAMICS; NONHUMAN; NUCLEAR REPROGRAMMING; OXYGEN TENSION; PHENOTYPE; PLASTICITY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEFICIENCY; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; TRANSACTIVATION; TUMOR GROWTH;

EID: 80052995658     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601911410224     Document Type: Article

References (227)

1. Lane DP.Cancer: p53, guardian of the genome.Nature. 1992;358:15-6.
2. Maddocks O,Vousden K.Metabolic regulation by p53.J Mol Med. 2011;89:237-45.
3. Muller PAJ,Vousden KH,Norman JC.p53 and its mutants in tumor cell migration and invasion.J Cell Biol. 2011;192:209-18.
4. Vousden KH,Lane DP.p53 in health and disease.Nat Rev Mol Cell Biol. 2007;8:275-83.
5. Hosako H,Little SA,Barrier M,Mirkes PE.Teratogen-induced activation of p53 in early postimplantation mouse embryos.Toxicol Sci. 2007;95:257-69.
6. Linke SP,Clarkin KC,Di Leonardo A,Tsou A,Wahl GM.A reversible, p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage.Genes Dev. 1996;10:934-47.
7. Vousden KH,Prives C.Blinded by the light: the growing complexity of p53.Cell. 2009;137:413-31.
8. Molchadsky A,Rivlin N,Brosh R,Rotter V,Sarig R.p53 is balancing development, differentiation and de-differentiation to assure cancer prevention.Carcinogenesis. 2010;31:1501-8.
9. Zhao Z,Zuber J,Diaz-Flores E, et al.p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal.Genes Dev. 2010;24:1389-402.
10. Lin T,Chao C,Saito Si, et al.p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression.Nat Cell Biol. 2005;7:165-71.
11. Meletis K,Wirta V,Hede S-M,Nister M,Lundeberg J,Frisen J.p53 suppresses the self-renewal of adult neural stem cells.Development. 2006;133:363-9.
12. Takahashi K,Tanabe K,Ohnuki M, et al.Induction of pluripotent stem cells from adult human fibroblasts by defined factors.Cell. 2007;131:861-72.
13. Zhao Y,Yin X,Qin H, et al.Two supporting factors greatly improve the efficiency of human iPSC generation.Cell Stem Cell. 2008;3:475-9.
14. Kawamura T,Suzuki J,Wang YV, et al.Linking the p53 tumour suppressor pathway to somatic cell reprogramming.Nature. 2009;460:1140-4.
15. Hong H,Takahashi K,Ichisaka T, et al.Suppression of induced pluripotent stem cell generation by the p53-p21 pathway.Nature. 2009;460:1132-5.
16. Li H,Collado M,Villasante A, et al.The Ink4/Arf locus is a barrier for iPS cell reprogramming.Nature. 2009;460:1136-9.
17. Marion RM,Strati K,Li H, et al.A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity.Nature. 2009;460:1149-53.
18. Utikal J,Polo JM,Stadtfeld M, et al.Immortalization eliminates a roadblock during cellular reprogramming into iPS cells.Nature. 2009;460:1145-8.
19. Sarig R,Rivlin N,Brosh R, et al.Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells.J Exp Med. 2009;207:2127-40.
20. Pierce GB,Speers WC.Tumors as caricatures of the process of tissue renewal: prospects for therapy by directing differentiation.Cancer Res. 1988;48:1996-2004.
21. Mizuno H,Spike BT,Wahl GM,Levine AJ.Inactivation of p53 in breast cancers correlates with stem cell transcriptional signatures.Proc Natl Acad Sci U S A. 2010;107:22745-50.
22. Linzer DIH,Levine AJ.Characterization of a 54K Dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells.Cell. 1979;17:43-52.
23. Lane D,Crawford L.T antigen is bound to a host protein in SV40-transformed cells.Nature. 1979;278:261-3.
24. Ben David Y,Prideaux VR,Chow V,Benchimol S,Bernstein A.Inactivation of the p53 oncogene by internal deletion or retroviral integration in erythroleukemic cell lines induced by Friend leukemia virus.Oncogene. 1988;3:179-85.
25. Mowat M,Cheng A,Kimura N,Bernstein A,Benchimol S.Rearrangements of the cellular p53 gene in erythroleukaemic cells transformed by Friend virus.Nature. 1985;314:633-6.
26. Wolf D,Rotter V.Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells.Proc Natl Acad Sci U S A. 1985;82:790-4.
27. Baker SJ,Fearon ER,Nigro JM, et al.Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas.Science. 1989;244:217-21.
28. Wolf D,Rotter V.Inactivation of p53 gene expression by an insertion of Moloney murine leukemia virus-like DNA sequences.Mol Cell Biol. 1984;4:1402-10.
29. Malkin D,Li FP,Strong LC, et al.Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms.Science. 1990;250:1233-8.
30. Jacks T,Remington L,Williams BO, et al.Tumor spectrum analysis in p53-mutant mice.Curr Biol. 1994;4:1-7.
31. Donehower LA,Harvey M,Slagle BL, et al.Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours.Nature. 1992;356:215-21.
32. Michalak EM,Vandenberg CJ,Delbridge ARD, et al.Apoptosis-promoted tumorigenesis: γ-irradiation-induced thymic lymphomagenesis requires Puma-driven leukocyte death.Genes Dev. 2010;24:1608-13.
33. Kuperwasser C,Hurlbut GD,Kittrell FS, et al.Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice: a model for Li-Fraumeni syndrome.Am J Pathol. 2000;157:2151-9.
34. Artandi SE,Chang S,Lee S-L, et al.Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice.Nature. 2000;406:641-5.
35. Jonkers J,Berns A.Conditional mouse models of sporadic cancer.Nat Rev Cancer. 2002;2:251-65.
36. Liu X,Holstege H,van der Gulden H, et al.Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer.Proc Natl Acad Sci U S A. 2007;104:12111-6.
37. Olivier M,Hollstein M,Hainaut P.TP53 mutations in human cancers: origins, consequences, and clinical use.Cold Spring Harb Perspect Biol. 2010;2:.
38. Soussi T,Wiman KG.Shaping genetic alterations in human cancer: the p53 mutation paradigm.Cancer Cell. 2007;12:303-12.
39. Lowe SW,Jacks T,Housman DE,Ruley HE.Abrogation of oncogene-associated apoptosis allows transformation of p53-deficient cells.Proc Natl Acad Sci U S A. 1994;91:2026-30.
40. Kastan MB,Onyekwere O,Sidransky D,Vogelstein B,Craig RW.Participation of p53 protein in the cellular response to DNA damage.Cancer Res. 1991;51:6304-11.
41. Lowe SW,Ruley HE,Jacks T,Housman DE.p53-dependent apoptosis modulates the cytotoxicity of anticancer agents.Cell. 1993;74:957-67.
42. He L,He X,Lim LP, et al.A microRNA component of the p53 tumour suppressor network.Nature. 2007;447:1130-4.
43. Suzuki HI,Yamagata K,Sugimoto K,Iwamoto T,Kato S,Miyazono K.Modulation of microRNA processing by p53.Nature. 2009;460:529-33.
44. Toledo F,Bardot B.Cancer: three birds with one stone.Nature. 2009;460:466-7.
45. Di Leonardo A,Linke SP,Clarkin K,Wahl GM.DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts.Genes Dev. 1994;8:2540-51.
46. Xue W,Zender L,Miething C, et al.Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas.Nature. 2007;445:656-60.
47. DuPage M,Cheung AF,Mazumdar C, et al.Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression.Cancer Cell. 2011;19:72-85.
48. Zilfou JT,Lowe SW.Tumor suppressive functions of p53.Cold Spring Harb Perspect Biol. 2009;1:.
49. Wade M,Wang YV,Wahl GM.The p53 orchestra: Mdm2 and Mdmx set the tone.Trends Cell Biol. 2010;20:299-309.
50. Hill R,Song Y,Cardiff RD,Van Dyke T.Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis.Cell. 2005;123:1001-11.
51. Wang YV,Wade M,Wahl GM.Guarding the guardian: Mdmx plays important roles in setting p53 basal activity and determining biological responses in vivo.Cell Cycle. 2009;8:3443-4.
52. Jackson MW,Berberich SJ.MdmX protects p53 from Mdm2-mediated degradation.Mol Cell Biol. 2000;20:1001-7.
53. Montes de Oca Luna R,Wagner DS,Lozano G.Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53.Nature. 1995;378:203-6.
54. Jones SN,Roe AE,Donehower LA,Bradley A.Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53.Nature. 1995;378:206-8.
55. GannonHSDonehowerLALyleSJonesSN. Mdm2-p53 signaling regulates epidermal stem cell senescence and premature aging phenotypes in mouse skin. Dev Biol. In press.
56. Marine JC,Francoz S,Maetens M,Wahl G,Toledo F,Lozano G.Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4.Cell Death Differ. 2006;13:927-34.
57. Alkema M,Wiegant J,Raap AK,Bems A,van Lohuizen M.Characterization and chromosomal localization of the human proto-oncogene BMI-1.Hum Mol Genet. 1993;2:1597-603.
58. Molofsky AV,Pardal R,Iwashita T,Park I-K,Clarke MF,Morrison SJ.Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation.Nature. 2003;425:962-7.
59. Park IK,Qian D,Kiel M, et al.Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells.Nature. 2003;423:302-5.
60. Pietersen AM,Evers B,Prasad AA, et al.Bmi1 regulates stem cells and proliferation and differentiation of committed cells in mammary epithelium.Curr Biol. 2008;18:1094-9.
61. Haupt Y,Alexander WS,Barri G,Peter Klinken S,Adams JM.Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in E mu-myc transgenic mice.Cell. 1991;65:753-63.
62. van Lohuizen M,Verbeek S,Scheljen B,Wientjens E,van der Guidon H,Berns A.Identification of cooperating oncogenes in Eμ-myc transgenic mice by provirus tagging.Cell. 1991;65:737-52.
63. Jacobs JJ,Scheijen B,Voncken JW,Kieboom K,Berns A,van Lohuizen M.Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF.Genes Dev. 1999;13:2678-90.
64. Lowe SW,Sherr CJ.Tumor suppression by Ink4a-Arf: progress and puzzles.Curr Opin Genet Dev. 2003;13:77-83.
65. Pomerantz J,Schreiber-Agus N,Liegeois NJ, et al.The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53.Cell. 1998;92:713-23.
66. Zhang Y,Xiong Y,Yarbrough WG.ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways.Cell. 1998;92:725-34.
67. Shakhova O,Leung C,Marino S.Bmi1 in development and tumorigenesis of the central nervous system.J Mol Med. 2005;83:596-600.
68. Stingl J,Eirew P,Ricketson I, et al.Purification and unique properties of mammary epithelial stem cells.Nature. 2006;439:993-7.
69. Shackleton M,Vaillant F,Simpson KJ, et al.Generation of a functional mammary gland from a single stem cell.Nature. 2006;439:84-8.
70. Sato T,Vries RG,Snippert HJ, et al.Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche.Nature. 2009;459:262-5.
71. Zeng YA,Nusse R.Wnt proteins are self-renewal factors for mammary stem cells and promote their long-term expansion in culture.Cell Stem Cell. 2010;6:568-77.
72. Yilmaz OH,Kiel MJ,Morrison SJ.SLAM family markers are conserved among hematopoietic stem cells from old and reconstituted mice and markedly increase their purity.Blood. 2006;107:924-30.
73. Morrison SJ,Uchida N,Weissman IL.The biology of hematopoietic stem cells.Annu Rev Cell Dev Biol. 1995;11:35-71.
74. Morrison SJ,Wandycz AM,Akashi K,Globerson A,Weissman IL.The aging of hematopoietic stem cells.Nat Med. 1996;2:1011-6.
75. Krause DS,Theise ND,Collector MI, et al.Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell.Cell. 2001;105:369-77.
76. Liu Y,Elf SE,Miyata Y, et al.p53 regulates hematopoietic stem cell quiescence.Cell Stem Cell. 2009;4:37-48.
77. Ito K,Hirao A,Arai F, et al.Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells.Nature. 2004;431:997-1002.
78. Spike BT,Dirlam A,Dibling BC, et al.The Rb tumor suppressor is required for stress erythropoiesis.EMBO J. 2004;23:4319-29.
79. Cheng T,Rodrigues N,Shen H, et al.Hematopoietic stem cell quiescence maintained by p21cip1/waf1.Science. 2000;287:1804-8.
80. van Os R,Kamminga LM,Ausema A, et al.A limited role for p21Cip1/Waf1 in maintaining normal hematopoietic stem cell functioning.Stem Cells. 2007;25:836-43.
81. Bondar T,Medzhitov R.p53-mediated hematopoietic stem and progenitor cell competition.Cell Stem Cell. 2010;6:309-22.
82. Marusyk A,DeGregori J.Declining cellular fitness with age promotes cancer initiation by selecting for adaptive oncogenic mutations.Biochim Biophys Acta. 2008;1785:1-11.
83. Akala OO,Park IK,Qian D,Pihalja M,Becker MW,Clarke MF.Long-term haematopoietic reconstitution by Trp53-/-p16Ink4a-/-p19Arf-/- multipotent progenitors.Nature. 2008;453:228-32.
84. Cicalese A,Bonizzi G,Pasi CE, et al.The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells.Cell. 2009;138:1083-95.
85. Tao L,Roberts AL,Dunphy KA,Bigelow C,Yan H,Jerry DJ.Repression of mammary stem/progenitor cells by p53 is mediated by Notch and separable from apoptotic activity.Stem Cells. 2011;29:119-27.
86. Gatza CE,Dumble M,Kittrell F, et al.Altered mammary gland development in the p53+/m mouse, a model of accelerated aging.Dev Biol. 2008;313:130-41.
87. Flores I,Blasco MA.A p53-dependent response limits epidermal stem cell functionality and organismal size in mice with short telomeres.PLoS ONE. 2009;4:e4934.
88. Zhou Z,Flesken-Nikitin A,Nikitin AY.Prostate cancer associated with p53 and Rb deficiency arises from the stem/progenitor cell-enriched proximal region of prostatic ducts.Cancer Res. 2007;67:5683-90.
89. Gil-Perotin S,Marin-Husstege M,Li J, et al.Loss of p53 induces changes in the behavior of subventricular zone cells: implication for the genesis of glial tumors.J Neurosci. 2006;26:1107-16.
90. Armesilla-Diaz A,Bragado P,Del Valle I, et al.p53 regulates the self-renewal and differentiation of neural precursors.Neuroscience. 2009;158:1378-89.
91. Zheng H,Ying H,Yan H, et al.p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation.Nature. 2008;455:1129-33.
92. Savatier P,Lapillonne H,van Grunsven LA,Rudkin BB,Samarut J.Withdrawal of differentiation inhibitory activity/leukemia inhibitory factor up-regulates D-type cyclins and cyclin-dependent kinase inhibitors in mouse embryonic stem cells.Oncogene. 1996;12:309-22.
93. Aladjem MI,Spike BT,Rodewald LW, et al.ES cells do not activate p53-dependent stress responses and undergo p53-independent apoptosis in response to DNA damage.Curr Biol. 1998;8:145-55.
94. Sabapathy K,Klemm M,Jaenisch R,Wagner EF.Regulation of ES cell differentiation by functional and conformational modulation of p53.EMBO J. 1997;16:6217-29.
95. Solozobova V,Rolletschek A,Blattner C.Nuclear accumulation and activation of p53 in embryonic stem cells after DNA damage.BMC Cell Biol. 2009;10:46.
96. Han MK,Song EK,Guo Y,Ou X,Mantel C,Broxmeyer HE.SIRT1 regulates apoptosis and Nanog expression in mouse embryonic stem cells by controlling p53 subcellular localization.Cell Stem Cell. 2008;2:241-51.
97. Chuykin IA,Lianguzova MS,Pospelova TV,Pospelov VA.Activation of DNA damage response signaling in mouse embryonic stem cells.Cell Cycle. 2008;7:2922-8.
98. Hong Y,Stambrook PJ.Restoration of an absent G1 arrest and protection from apoptosis in embryonic stem cells after ionizing radiation.Proc Natl Acad Sci U S A. 2004;101:14443-8.
99. Hong Y,Cervantes RB,Tichy E,Tischfield JA,Stambrook PJ.Protecting genomic integrity in somatic cells and embryonic stem cells.Mutat Res. 2007;614:48-55.
100. de Vries A,Flores ER,Miranda B, et al.Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function.Proc Natl Acad Sci U S A. 2002;99:2948-53.
101. Lee KH,Li M,Michalowski AM, et al.A genomewide study identifies the Wnt signaling pathway as a major target of p53 in murine embryonic stem cells.Proc Natl Acad Sci U S A. 2010;107:69-74.
102. Fluckiger AC,Marcy G,Marchand M, et al.Cell cycle features of primate embryonic stem cells.Stem Cells. 2006;24:547-56.
103. Prost S,Bellamy CO,Clarke AR,Wyllie AH,Harrison DJ.p53-independent DNA repair and cell cycle arrest in embryonic stem cells.FEBS Lett. 1998;425:499-504.
104. Qin H,Yu T,Qing T, et al.Regulation of apoptosis and differentiation by p53 in human embryonic stem cells.J Biol Chem. 2007;282:5842-52.
105. Stead E,White J,Faast R, et al.Pluripotent cell division cycles are driven by ectopic Cdk2, cyclin A/E and E2F activities.Oncogene. 2002;21:8320-33.
106. Koledova Z,Kafkova LR,Calabkova L,Krystof V,Dolezel P,Divoky V.Cdk2 inhibition prolongs G1 phase progression in mouse embryonic stem cells.Stem Cells Dev. 2010;19:181-94.
107. Neganova I,Lako M.G1 to S phase cell cycle transition in somatic and embryonic stem cells.J Anat. 2008;213:30-44.
108. Lombard DB,Chua KF,Mostoslavsky R,Franco S,Gostissa M,Alt FW.DNA repair, genome stability, and aging.Cell. 2005;120:497-512.
109. Balaban RS,Nemoto S,Finkel T.Mitochondria, oxidants, and aging.Cell. 2005;120:483-95.
110. Vafa O,Wade M,Kern S, et al.c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability.Mol Cell. 2002;9:1031-44.
111. Macleod KF.The RB tumor suppressor: a gatekeeper to hormone independence in prostate cancer?.J Clin Invest. 2010;120:4179-82.
112. Dean JB,Mulkey DK,Henderson RA,Potter SJ,Putnam RW.Hyperoxia, reactive oxygen species, and hyperventilation: oxygen sensitivity of brain stem neurons.J Appl Physiol. 2004;96:784-91.
113. Kurz EU,Douglas P,Lees-Miller SP.Doxorubicin activates ATM-dependent phosphorylation of multiple downstream targets in part through the generation of reactive oxygen species.J Biol Chem. 2004;279:53272-81.
114. Courtois S,Verhaegh G,North S, et al.DeltaN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53.Oncogene. 2002;21:6722-8.
115. Ungewitter E,Scrable H.DeltaN40-p53 controls the switch from pluripotency to differentiation by regulating IGF signaling in ESCs.Genes Dev. 2010;24:2408-19.
116. Melis JP,Hoogervorst EM,van Oostrom CT, et al.Genotoxic exposure: novel cause of selection for a functional DeltaN-p53 isoform.Oncogene. 2011;14:1764-72.
117. Bourdon JC,Fernandes K,Murray-Zmijewski F, et al.p53 isoforms can regulate p53 transcriptional activity.Genes Dev. 2005;19:2122-37.
118. Xu D,Wilson TJ,Chan D, et al.Ets1 is required for p53 transcriptional activity in UV-induced apoptosis in embryonic stem cells.EMBO J. 2002;21:4081-93.
119. Menendez S,Goh AM,Camus S, et al.MDM4 downregulates p53 transcriptional activity and response to stress during differentiation.Cell Cycle. 2011;10:1100-8.
120. Choong ML,Yang H,Lee MA,Lane DP.Specific activation of the p53 pathway by low dose actinomycin D: a new route to p53 based cyclotherapy.Cell Cycle. 2009;8:2810-8.
121. Vassilev LT,Vu BT,Graves B, et al.In vivo activation of the p53 pathway by small-molecule antagonists of MDM2.Science. 2004;303:844-8.
122. Ginis I,Luo Y,Miura T, et al.Differences between human and mouse embryonic stem cells.Dev Biol. 2004;269:360-80.
123. Neganova I,Vilella F,Atkinson SP, et al.An important role for CDK2 in G1 to S checkpoint activation and DNA damage response in human embryonic stem cells.Stem Cells. 2011;29:651-9.
124. Becker KA,Ghule PN,Therrien JA, et al.Self-renewal of human embryonic stem cells is supported by a shortened G1 cell cycle phase.J Cell Physiol. 2006;209:883-93.
125. Filion TM,Qiao M,Ghule PN, et al.Survival responses of human embryonic stem cells to DNA damage.J Cell Physiol. 2009;220:586-92.
126. Wilson KD,Sun N,Huang M, et al.Effects of ionizing radiation on self-renewal and pluripotency of human embryonic stem cells.Cancer Res. 2010;70:5539-48.
127. Barta T,Vinarsky V,Holubcova Z, et al.Human embryonic stem cells are capable of executing G1/S checkpoint activation.Stem Cells. 2011;28:1143-52.
128. Maimets T,Neganova I,Armstrong L,Lako M.Activation of p53 by nutlin leads to rapid differentiation of human embryonic stem cells.Oncogene. 2008;27:5277-87.
129. Chou YF,Chen HH,Eijpe M, et al.The growth factor environment defines distinct pluripotent ground states in novel blastocyst-derived stem cells.Cell. 2008;135:449-61.
130. Neveu P,Kye MJ,Qi S, et al.MicroRNA profiling reveals two distinct p53-related human pluripotent stem cell states.Cell Stem Cell. 2011;7:671-81.
131. Brons IG,Smithers LE,Trotter MW, et al.Derivation of pluripotent epiblast stem cells from mammalian embryos.Nature. 2007;448:191-5.
132. Tesar PJ,Chenoweth JG,Brook FA, et al.New cell lines from mouse epiblast share defining features with human embryonic stem cells.Nature. 2007;448:196-9.
133. Buecker C,Chen H-H,Polo JM, et al.A murine ESC-like state facilitates transgenesis and homologous recombination in human pluripotent stem cells.Cell Stem Cell. 2010;6:535-46.
134. Yang A,Kaghad M,Caput D,McKeon F.On the shoulders of giants: p63, p73 and the rise of p53.Trends Genet. 2002;18:90-5.
135. Senoo M,Pinto F,Crum CP,McKeon F.p63 is essential for the proliferative potential of stem cells in stratified epithelia.Cell. 2007;129:523-36.
136. Moll UM,Slade N.p63 and p73: roles in development and tumor formation.Mol Cancer Res. 2004;2:371-86.
137. Rocco JW,Leong C-O,Kuperwasser N,DeYoung MP,Ellisen LW.p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis.Cancer Cell. 2006;9:45-56.
138. Suh EK,Yang A,Kettenbach A, et al.p63 protects the female germ line during meiotic arrest.Nature. 2006;444:624-8.
139. Aubrecht J,Secretan MB,Bishop AJ,Schiestl RH.Involvement of p53 in X-ray induced intrachromosomal recombination in mice.Carcinogenesis. 1999;20:2229-36.
140. Baatout S,Jacquet P,Michaux A, et al.Developmental abnormalities induced by X-irradiation in p53 deficient mice.In Vivo. 2002;16:215-21.
141. Armstrong JF,Kaufman MH,Harrison DJ,Clarke AR.High-frequency developmental abnormalities in p53-deficient mice.Curr Biol. 1995;5:931-6.
142. Belyi VA,Ak P,Markert E, et al.The origins and evolution of the p53 family of genes.Cold Spring Harb Perspect Biol. 2010;2:.
143. Crum CP,McKeon FD.p63 in epithelial survival, germ cell surveillance, and neoplasia.Annu Rev Pathol. 2010;5:349-71.
144. Talos F,Nemajerova A,Flores ER,Petrenko O,Moll UM.p73 suppresses polyploidy and aneuploidy in the absence of functional p53.Mol Cell. 2007;27:647-59.
145. Jacks T,Remington L,Williams BO, et al.Tumor spectrum analysis in p53-mutant mice.Curr Biol. 1994;4:1-7.
146. Hu W,Feng Z,Teresky AK,Levine AJ.p53 regulates maternal reproduction through LIF.Nature. 2007;450:721-4.
147. Rotter V,Schwartz D,Almon E, et al.Mice with reduced levels of p53 protein exhibit the testicular giant-cell degenerative syndrome.Proc Natl Acad Sci U S A. 1993;90:9075-9.
148. Beumer TL,Roepers-Gajadien HL,Gademan IS, et al.The role of the tumor suppressor p53 in spermatogenesis.Cell Death Differ. 1998;5:669-77.
149. Sah VP,Attardi LD,Mulligan GJ,Williams BO,Bronson RT,Jacks T.A subset of p53- deficient embryos exhibit exencephaly.Nat Genet. 1995;10:175-80.
150. MacCallum DE,Hupp TR,Midgley CA, et al.The p53 response to ionising radiation in adult and developing murine tissues.Oncogene. 1996;13:2575-87.
151. Gottlieb E,Haffner R,King A, et al.Transgenic mouse model for studying the transcriptional activity of the p53 protein: age- and tissue-dependent changes in radiation-induced activation during embryogenesis.EMBO J. 1997;16:1381-90.
152. Komarova EA,Chernov MV,Franks R, et al.Transgenic mice with p53-responsive lacZ: p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivo.EMBO J. 1997;16:1391-400.
153. Almog N,Rotter V.Involvement of p53 in cell differentiation and development.Biochim Biophys Acta. 1997;1333:F1-27.
154. Matas D,Milyavsky M,Shats I,Nissim L,Goldfinger N,Rotter V.p53 is a regulator of macrophage differentiation.Cell Death Differ. 2004;11:458-67.
155. Tsukada T,Tomooka Y,Takai S, et al.Enhanced proliferative potential in culture of cells from p53-deficient mice.Oncogene. 1993;8:3313-22.
156. Macleod KF,Hu Y,Jacks T.Loss of Rb activates both p53-dependent and independent cell death pathways in the developing mouse nervous system.EMBO J. 1996;15:6178-88.
157. Porrello A,Cerone MA,Coen S, et al.p53 regulates myogenesis by triggering the differentiation activity of pRb.J Cell Biol. 2000;151:1295-304.
158. Molchadsky A,Shats I,Goldfinger N, et al.p53 plays a role in mesenchymal differentiation programs, in a cell fate dependent manner.PLoS ONE. 2008;3:e3707.
159. Hallenborg P,Feddersen S,Madsen L,Kristiansen K.The tumor suppressors pRB and p53 as regulators of adipocyte differentiation and function.Expert Opin Ther Targets. 2009;13:235-46.
160. TeKippe M,Harrison DE,Chen J.Expansion of hematopoietic stem cell phenotype and activity in Trp53-null mice.Exp Hematol. 2003;31:521-7.
161. Zhao T,Xu Y.p53 and stem cells: new developments and new concerns.Trends Cell Biol. 2010;20:170-5.
162. Mora-Castilla S,Tejedo JR,Hmadcha A, et al.Nitric oxide repression of Nanog promotes mouse embryonic stem cell differentiation.Cell Death Differ. 2010;17:1025-33.
163. Ostrakhovitch EA,Semenikhin OA.p53- mediated regulation of neuronal differentiation via regulation of dual oxidase maturation factor 1.Neurosci Lett. 2011;494:80-5.
164. Fiucci G,Beaucourt S,Duflaut D, et al.Siah-1b is a direct transcriptional target of p53: identification of the functional p53 responsive element in the siah-1b promoter.Proc Natl Acad Sci U S A. 2004;101:3510-5.
165. Iwai A,Marusawa H,Matsuzawa S, et al.Siah-1L, a novel transcript variant belonging to the human Siah family of proteins, regulates beta-catenin activity in a p53-dependent manner.Oncogene. 2004;23:7593-600.
166. Pece S,Tosoni D,Confalonieri S, et al.Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content.Cell. 2010;140:62-73.
167. Knoblich JA,Jan LY,Jan YN.Asymmetric segregation of Numb and Prospero during cell division.Nature. 1995;377:624-7.
168. Wu M,Kwon HY,Rattis F, et al.Imaging hematopoietic precursor division in real time.Cell Stem Cell. 2007;1:541-54.
169. Colaluca IN,Tosoni D,Nuciforo P, et al.NUMB controls p53 tumour suppressor activity.Nature. 2008;451:76-80.
170. Pereira L,Yi F,Merrill BJ.Repression of Nanog gene transcription by Tcf3 limits embryonic stem cell self-renewal.Mol Cell Biol. 2006;26:7479-91.
171. Ruiz S,Panopoulos AD,Herrerías A, et al.A high proliferation rate is required for cell reprogramming and maintenance of human embryonic stem cell identity.Curr Biol. 2011;21:45-52.
172. Fagin JA,Matsuo K,Karmakar A,Chen DL,Tang SH,Koeffler HP.High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas.J Clin Invest. 1993;91:179-84.
173. Miller LD,Smeds J,George J, et al.An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival.Proc Natl Acad Sci U S A. 2005;102:13550-5.
174. de Cremoux P,Salomon AV,Liva S, et al.p53 mutation as a genetic trait of typical medullary breast carcinoma.J Natl Cancer Inst. 1999;91:641-3.
175. Kochhar R,Howard EM,Umbreit JN,Lau SK.Metaplastic breast carcinoma with squamous differentiation: molecular and clinical analysis of six cases.Breast J. 2005;11:367-9.
176. Zheng H,Ying H,Yan H, et al.p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation.Nature. 2008;455:1129-33.
177. Junttila MR,Karnezis AN,Garcia D, et al.Selective activation of p53-mediated tumour suppression in high-grade tumours.Nature. 2010;468:567-71.
178. Feldser DM,Kostova KK,Winslow MM, et al.Stage-specific sensitivity to p53 restoration during lung cancer progression.Nature. 2010;468:572-5.
179. Burger H,Nooter K,Boersma AWM,Kortland CJ,Stoter G.Lack of correlation between cisplatin-induced apoptosis, p53 status and expression of Bcl-2 family proteins in testicular germ cell tumour cell lines.Int J Cancer. 1997;73:592-9.
180. Oren M,Reich NC,Levine AJ.Regulation of the cellular p53 tumor antigen in teratocarcinoma cells and their differentiated progeny.Mol Cell Biol. 1982;2:443-9.
181. Kemp CJ,Donehower LA,Bradley A,Balmain A.Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors.Cell. 1993;74:813-22.
182. Jiang Z,Deng T,Jones R, et al.Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status.J Clin Invest. 2010;120:3296-309.
183. Chylicki K,Ehinger M,Svedberg H,Gullberg U.Characterization of the molecular mechanisms for p53-mediated differentiation.Cell Growth Differ. 2000;11:561-71.
184. Johnson P,Chung S,Benchimol S.Growth suppression of Friend virus-transformed erythroleukemia cells by p53 protein is accompanied by hemoglobin production and is sensitive to erythropoietin.Mol Cell Biol. 1993;13:1456-63.
185. Feinstein E,Gale RP,Reed J,Canaani E.Expression of the normal p53 gene induces differentiation of K562 cells.Oncogene. 1992;7:1853-7.
186. Secchiero P,Zerbinati C,Melloni E, et al.The MDM-2 antagonist nutlin-3 promotes the maturation of acute myeloid leukemic blasts.Neoplasia. 2007;9:853-61.
187. Lang D,Miknyoczki SJ,Huang L,Ruggeri BA.Stable reintroduction of wild-type P53 (MTmp53ts) causes the induction of apoptosis and neuroendocrine-like differentiation in human ductal pancreatic carcinoma cells.Oncogene. 1998;16:1593-602.
188. Radinsky R,Fidler IJ,Price JE, et al.Terminal differentiation and apoptosis in experimental lung metastases of human osteogenic sarcoma cells by wild type p53.Oncogene. 1994;9:1877-83.
189. Bond JA,Oddweig Ness G,Rowson J,Ivan M,White D,Wynford-Thomas D.Spontaneous de-differentiation correlates with extended lifespan in transformed thyroid epithelial cells: an epigenetic mechanism of tumour progression?.Int J Cancer. 1996;67:563-72.
190. Kleinsmith LJ,Pierce GB.Multipotentiality of single embryonal carcinoma cells.Cancer Res. 1964;24:1544-51.
191. Martin GR.Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells.Proc Natl Acad Sci U S A. 1981;78:7634-8.
192. Casimir CM,Gates PB,Patient RK,Brockes JP.Evidence for dedifferentiation and metaplasia in amphibian limb regeneration from inheritance of DNA methylation.Development. 1988;104:657-68.
193. Takahashi K,Okita K,Nakagawa M,Yamanaka S.Induction of pluripotent stem cells from fibroblast cultures.Nat Protoc. 2007;2:3081-9.
194. Tapia N,Scholer HR.p53 connects tumorigenesis and reprogramming to pluripotency.J Exp Med. 2010;207:2045-8.
195. Pelengaris S,Khan M,Evan G.c-MYC: more than just a matter of life and death.Nat Rev Cancer. 2002;2:764-76.
196. Hanna J,Saha K,Pando B, et al.Direct cell reprogramming is a stochastic process amenable to acceleration.Nature. 2009;462:595-601.
197. Smith ZD,Nachman I,Regev A,Meissner A.Dynamic single-cell imaging of direct reprogramming reveals an early specifying event.Nat Biotechnol. 2010;28:521-6.
198. Lister R,Pelizzola M,Kida YS, et al.Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells.Nature. 2011;471:68-73.
199. Assou S,Le Carrour T,Tondeur S, et al.A meta-analysis of human embryonic stem cells transcriptome integrated into a web-based expression atlas.Stem Cells. 2007;25:961-73.
200. Ben-Porath I,Thomson MW,Carey VJ, et al.An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors.Nat Genet. 2008;40:499-507.
201. Kim J,Woo AJ,Chu J, et al.A Myc network accounts for similarities between embryonic stem and cancer cell transcription programs.Cell. 2010;143:313-24.
202. Wong DJ,Liu H,Ridky TW,Cassarino D,Segal E,Chang HY.Module map of stem cell genes guides creation of epithelial cancer stem cells.Cell Stem Cell. 2008;2:333-44.
203. Muller FJ,Schuldt BM,Williams R, et al.A bioinformatic assay for pluripotency in human cells.Nat Methods. 2011;8:315-7.
204. Chapman MA,Lawrence MS,Keats JJ, et al.Initial genome sequencing and analysis of multiple myeloma.Nature. 2011;471:467-72.
205. Berger MF,Lawrence MS,Demichelis F, et al.The genomic complexity of primary human prostate cancer.Nature. 2011;470:214-20.
206. Navin N,Kendall J,Troge J, et al.Tumour evolution inferred by single-cell sequencing.Nature. 2011;472:90-4.
207. Bonnet D,Dick JE.Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell.Nat Med. 1997;3:730-7.
208. Reya T,Morrison SJ,Clarke MF,Weissman IL.Stem cells, cancer, and cancer stem cells.Nature. 2001;414:105-11.
209. Al-Hajj M,Wicha MS,Benito-Hernandez A,Morrison SJ,Clarke MF.Prospective identification of tumorigenic breast cancer cells.Proc Natl Acad Sci U S A. 2003;100:3983-8.
210. Passegue E,Jamieson CH,Ailles LE,Weissman IL.Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics?.Proc Natl Acad Sci U S A. 2003;100 (Suppl 1): 11842-9.
211. Henry MD,Triplett AA,Oh KB,Smith GH,Wagner KU.Parity-induced mammary epithelial cells facilitate tumorigenesis in MMTV-neu transgenic mice.Oncogene. 2004;23:6980-5.
212. Bouras T,Pal B,Vaillant F, et al.Notch signaling regulates mammary stem cell function and luminal cell-fate commitment.Cell Stem Cell. 2008;3:429-41.
213. Barker N,Ridgway RA,van Es JH, et al.Crypt stem cells as the cells-of-origin of intestinal cancer.Nature. 2009;457:608-11.
214. Brown K,Strathdee D,Bryson S,Lambie W,Balmain A.The malignant capacity of skin tumours induced by expression of a mutant H-ras transgene depends on the cell type targeted.Curr Biol. 1998;8:516-24.
215. Clevers H.The cancer stem cell: premises, promises and challenges.Nat Med. 2011;17:313-9.
216. Langerod A,Zhao H,Borgan O, et al.TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer.Breast Cancer Res. 2007;9:R30.
217. Molyneux G,Geyer FC,Magnay FA, et al.BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells.Cell Stem Cell. 2010;7:403-17.
218. Molyneux G,Smalley M.The cell of origin of BRCA1 mutation-associated breast cancer: a cautionary tale of gene expression profiling.J Mammary Gland Biol Neoplasia. 2011;16:51-5.
219. Quintana E,Shackleton M,Foster HR, et al.Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized.Cancer Cell. 2008;18:510-23.
220. Roesch A,Fukunaga-Kalabis M,Schmidt EC, et al.A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth.Cell. 2010;141:583-94.
221. Quintana E,Shackleton M,Foster HR, et al.Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized.Cancer Cell. 2010;18:510-23.
222. Meyer MJ,Fleming JM,Lin AF,Hussnain SA,Ginsburg E,Vonderhaar BK.CD44posCD49fhiCD133/2hi defines xenograft-initiating cells in estrogen receptor-negative breast cancer.Cancer Res. 2010;70:4624-33.
223. Godar S,Ince TA,Bell GW, et al.Growth-inhibitory and tumor- suppressive functions of p53 depend on its repression of CD44 expression.Cell. 2008;134:62-73.
224. Liu C,Kelnar K,Liu B, et al.The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44.Nat Med. 2011;17:211-5.
225. Soda Y,Marumoto T,Friedmann-Morvinski D, et al.Transdifferentiation of glioblastoma cells into vascular endothelial cells.Proc Natl Acad Sci U S A. 2011;108:4274-80.
226. Sharma SV,Lee DY,Li B, et al.A chromatin- mediated reversible drug-tolerant state in cancer cell subpopulations.Cell. 2010;141:69-80.
227. Hough SR,Laslett AL,Grimmond SB,Kolle G,Pera MF.A continuum of cell states spans pluripotency and lineage commitment in human embryonic stem cells.PLoS ONE. 2009;4:e7708.